Works matching IS 13596535 AND DT 2022 AND VI 27 AND IP 2

Results: 19

Changes in blood lipids in patients with chronic hepatitis B after 48 weeks of tenofovir alafenamide treatment: A prospective real-world clinical study.

Published in:

Antiviral Therapy, 2022, v. 27, n. 2, p. 1, doi. 10.1177/13596535221082399

By:

Yeqiong Zhang;
Zhipeng Li;
Qiumin Luo;
Wenxiong Xu;
Lu Wang;
Shu Zhu;
Liang Peng;
Chan Xie

Publication type:

Article

Polaris Observatory—supporting informed decision-making at the national, regional, and global levels to eliminate viral hepatitis.

Published in:

Antiviral Therapy, 2022, v. 27, n. 2, p. 1, doi. 10.1177/13596535221083179

By:

Razavi, Homie

Publication type:

Article

Journey of remdesivir from the inhibition of hepatitis C virus to the treatment of COVID-19.

Published in:

Antiviral Therapy, 2022, v. 27, n. 2, p. 1, doi. 10.1177/13596535221082773

By:

Cihlar, Tomas;
Mackman, Richard L.

Publication type:

Article

Efficacy of second-line dolutegravir plus 2 nucleoside reverse transcriptase inhibitors by baseline nucleoside reverse transcriptase inhibitor resistance and nucleoside reverse transcriptase inhibitor use in the DAWNING study.

Published in:

Antiviral Therapy, 2022, v. 27, n. 2, p. 1, doi. 10.1177/13596535221077487

By:

Brown, Dannae;
Kaplan, Richard;
Losso, Marcelo;
Brites, Carlos;
Ruolan Wang;
Underwood, Mark;
Hopking, Judy;
Aboud, Michael;
Sievers, Jörg

Publication type:

Article

The role of tenofovir disoproxil fumarate for preventing vertical transmission of hepatitis B.

Published in:

Antiviral Therapy, 2022, v. 27, n. 2, p. 1, doi. 10.1177/13596535221076640

By:

Pan, Calvin Q.

Publication type:

Article

A rare complication of coronary vasospasm associated with concomitant use of ergotamine, cobicistat, and darunavir.

Published in:

Antiviral Therapy, 2022, v. 27, n. 2, p. 1, doi. 10.1177/13596535211068957

By:

Cheng-En Wu;
Chun-Hsien Wu;
Shih-Hung Tsai;
Wen-I Liao

Publication type:

Article

The curing regimens of HCV: A SWOT analysis.

Published in:

Antiviral Therapy, 2022, v. 27, n. 2, p. 1, doi. 10.1177/13596535211072672

By:

Cornberg, Markus;
Manns, Michael P.

Publication type:

Article

Providing access to high-quality, low-cost medicines across low and middle-income countries (LMICs), working with governments and generic manufacturers around the globe - A business case.

Published in:

Antiviral Therapy, 2022, v. 27, n. 2, p. 1, doi. 10.1177/13596535211068617

By:

Alton, Gregg;
Samuel, Clifford;
Reddi, Anand

Publication type:

Article

Commentary: John C. Martin (1951–2021).

Published in:

Antiviral Therapy, 2022, v. 27, n. 2, p. 1, doi. 10.1177/13596535211067895

By:

Lou, Lillian L.;
Flood, Amy;
Yang, Taiyin;
Whitley, Richard J.

Publication type:

Article

Discovery and development of oseltamivir at Gilead Sciences.

Published in:

Antiviral Therapy, 2022, v. 27, n. 2, p. 1, doi. 10.1177/13596535211067598

By:

Schmitz, Uli;
Swaminathan, Swami

Publication type:

Article

Case study of hepatitis C virus control in Egypt: impact of access program.

Published in:

Antiviral Therapy, 2022, v. 27, n. 2, p. 1, doi. 10.1177/13596535211067592

By:

Waked, Imam

Publication type:

Article

Antiviral prophylaxis for hepatitis B virus in COVID-19 patients treated with immunosuppressive drug therapy.

Published in:

Antiviral Therapy, 2022, v. 27, n. 2, p. 1, doi. 10.1177/13596535211067602

By:

Mastroianni, Antonio;
Greco, Sonia;
Chidichimo, Luciana;
Mauro, Maria Vittoria;
Urso, Filippo;
Vangeli, Valeria

Publication type:

Article

Tenofovir alafenamide fumarate.

Published in:

Antiviral Therapy, 2022, v. 27, n. 2, p. 1, doi. 10.1177/13596535211067600

By:

Lee, William A.;
Cheng, Andrew K.

Publication type:

Article

The best backbone for HIV prevention, treatment, and elimination: Emtricitabine+tenofovir.

Published in:

Antiviral Therapy, 2022, v. 27, n. 2, p. 1, doi. 10.1177/13596535211067599

By:

Schinazi, Raymond F.;
Patel, Dharmeshkumar;
Ehteshami, Maryam

Publication type:

Article

The making of the one pill—Developing single tablet regimens for HIV and for HCV.

Published in:

Antiviral Therapy, 2022, v. 27, n. 2, p. 1, doi. 10.1177/13596535211067606

By:

Taiyin Yang;
Oliyai, Reza;
Kent, Kenneth M.

Publication type:

Article

Adefovir for lamivudine-resistant hepatitis B.

Published in:

Antiviral Therapy, 2022, v. 27, n. 2, p. 1, doi. 10.1177/13596535211067605

By:

Roediger, Rebecca;
Smyth, Elizabeth Kula;
Dieterich, Douglas

Publication type:

Article

Advancing HIV prevention using tenofovir-based pre-exposure prophylaxis.

Published in:

Antiviral Therapy, 2022, v. 27, n. 2, p. 1, doi. 10.1177/13596535211067589

By:

Abdool Karim, Salim S.;
Baxter, Cheryl;
Karim, Quarraisha Abdool

Publication type:

Article

The transformation of HIV therapy: One pill once a day.

Published in:

Antiviral Therapy, 2022, v. 27, n. 2, p. 1, doi. 10.1177/13596535211062396

By:

Choudhary, Madhu C.;
Mellors, John W.

Publication type:

Article

Commentary: Development of Therapeutics for Congenital Cytomegalovirus Infection.

Published in:

Antiviral Therapy, 2022, v. 27, n. 2, p. 1, doi. 10.1177/13596535211060968

By:

Whitley, Richard J.

Publication type:

Article